Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “modified”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 505 records · Page 28Linked to original sources
PubMed1998

Evaluation of enzymatically modified potato starches in diets for weanling pigs.

We conducted three growth trials to evaluate replacing carbohydrate sources with enzymatically modified potato starches in diets for weanling pigs. In Exp. 1, 180 pigs (initially 5.3 kg and 21+/-2 d of age) were used to compare the effects of corn (36.5%), edible-grade oat flour (36.5%), two enzymatically modified potato starches (12%), and added lactose (12%) on pig performance. Potato Starch 1 had a dextrose equivalent (DE) of 6 and Potato Starch 2 had a DE of 20; both were spray-dried maltodextrans. Pigs that were fed Potato Starch 2 had greater (P<.05) ADG and ADFI than pigs fed diets that contained corn or oat flour from d 0 to 14 after weaning, and pigs fed either Potato Starch 1 or added lactose had intermediate ADG and ADFI. However, for the overall trial (d 0 to 35), no differences (P>.10) in growth performance were observed. In Exp. 2, 198 pigs (initially 4.3 kg and 19+/-2 d of age) were used to determine whether modified Potato Starch 2 could replace a portion of the corn or lactose in the diet. The control diet contained 10% dried whey, and additional treatments were formulated by adding 7 or 14% modified Potato Starch 2 or lactose in place of corn. A positive control diet was formulated containing 29% dried whey. From d 0 to 14 after weaning, increasing dietary lactose improved (linear, P<.04) ADG and ADFI. Increasing the potato starch had no effect on ADG but increased ADFI (linear, P<.02). In Exp. 3, 180 pigs (initially 3.9 kg and 14+/-3 d of age) were used to evaluate Potato Starch 2 or 3 (DE = 30, a spray-dried glucose syrup) as replacements for either corn or lactose in the diet. Pigs were fed a control diet containing 15% dried whey and 12% added lactose. Twelve percent modified Potato Starch 2 or 3 replaced either corn or lactose in the diet on a wt/wt basis. From d 0 to 14 and d 0 to 21, pigs fed either modified potato starch substituted for corn had greater (P<.07) ADG than those fed the control diet. Pigs fed diets with either modified starch substituted for lactose had similar ADG as those fed the control diet. These results suggest that when substituted for corn, Potato Starch 2 can improve growth performance of weanling pigs.

Animal Feed↗
PubMedDate not supplied

Control release of prostaglandin E2 from polylactic acid microcapsules, microparticles and modified microparticles.

Low molecular weight polylactic acid (PLA) microparticles containing prostaglandin E2 were prepared. An average particle size of 30 micron was obtained by grinding at low temperature. These particles were further treated by heating to modify the shape and the release pattern. Microscopic studies showed that the modified particles had a smoother surface than the non-modified particles. The drug was also incorporated into PLA microcapsules using the solvent evaporation process, but the incorporation efficiency was lower. We studied the release profiles of modified particles prepared using different molecular weight PLA. The release rate depended on the molecular weight with lower molecular weights having a greater release rate. In addition, the release studies showed different matrix forms made from the same molecular weight PLA had different release patterns. For example, the microcapsules released the drug very slowly whereas the modified particles exhibited a moderate release rate. It was also noted that the matrix release model could describe the release patterns of microcapsules and modified particles very well. However, the release patterns of non-modified microparticles did not follow this model.

Capsules↗
PubMed2001

A survey of lipolytic and glycolytic end-products in commercial Cheddar enzyme-modified cheese.

The concentrations of L- and D-lactic acid and free fatty acids, C4:0 to C18:3, were quantified in a range of commercial enzyme-modified Cheddar cheeses. Lactic acid in Cheddar enzyme-modified cheeses varied markedly depending on the manufacturer. Differences in the ratio of L- to D-lactic acid indicate that cheeses of different age were used in their manufacture or contained varying levels of nonstarter lactic acid bacteria. The level of lipolysis in enzyme-modified cheese was higher than in natural Cheddar cheese; butyrate was the predominant free fatty acid. The addition of exogenous acetate, lactate, and butyrate was also indicated in some enzyme-modified cheeses and may be used to confer a specific flavor characteristic or reduce the pH of the product. Propionate was also found in some enzyme-modified cheese products and most likely originated from Swiss-type cheese used in their manufacture. Propionate is not normally associated with natural Cheddar cheese flavor; however, it may be important in the flavor and aroma of Cheddar enzyme-modified cheese. Levels of lipolysis and glycolysis appear to highly controlled as interbatch variability was generally low. Overall, the production of enzyme-modified Cheddar cheese involves manipulation of the end-products of glycolysis (lactate, propionate, and acetate) and lipolysis to generate products for specific applications.

Acetates↗
PubMed2006

Modified versus producer milk calibration: mid-infrared analyzer performance validation.

Our objective was to determine the validation performance of mid-infrared (MIR) milk analyzers, using the traditional fixed-filter approach, when the instruments were calibrated with producer milk calibration samples vs. modified milk calibration samples. Ten MIR analyzers were calibrated using producer milk calibration sample sets, and 9 MIR milk analyzers were calibrated using modified milk sample sets. Three sets of 12 validation milk samples with all-laboratory mean chemistry reference values were tested during a 3-mo period. Calibration of MIR milk analyzers using modified milk increased the accuracy (i.e., better agreement with chemistry) and improved agreement between laboratories on validation milk samples compared with MIR analyzers calibrated with producer milk samples. Calibration of MIR analyzers using modified milk samples reduced overall mean Euclidian distance for all components for all 3 validation sets by at least 24% compared with MIR analyzers calibrated with producer milk sets. Calibration with modified milk sets reduced the average Euclidian distance from all-laboratory mean reference chemistry on validation samples by 40, 25, 36, and 27%, respectively for fat, anhydrous lactose, true protein, and total solids. Between-laboratory agreement was evaluated using reproducibility standard deviation (s(R)). The number of single Grubbs statistical outliers in the validation data was much higher (53 vs. 7) for the instruments calibrated with producer milk than for instruments calibrated with modified milk sets. The s(R) for instruments calibrated with producer milks (with statistical outliers removed) was similar to data collected in recent proficiency studies, whereas the s(R) for instruments calibrated with modified milks was lower than those calibrated with producer milks by 46, 52, 61, and 55%, respectively for fat, anhydrous lactose, true protein, and total solids.

Animals↗
PubMed1993

The role of biological response modifiers in disease control.

Immune responses to infectious agents involve a complex set of interactions between cells and the factors they produce that culminate with disease resolution or death. Therefore, the manipulation of the immune system may have a great impact on the preservation and restoration of animal health. Biological response modifiers are agents that modify the host's response to pathogens with resultant beneficial prophylactic or therapeutic effects. The best known example of biological response modifiers are vaccines, by which administration of a nonpathogenic form of a microorganism prepares the immune system to produce a more effective response upon subsequent infection with the pathogenic form. Nevertheless, the use of biological response modifiers other than vaccines that enhance the immune response is now the focus of many investigations. In this review, a brief overview of the immune system is presented, and special emphasis is placed on possible areas of intervention with biological response modifiers and a description of the prophylactic and therapeutic potential of biological response modifiers. Specific examples are presented to demonstrate examples of disease modification by biological response modifiers through stimulation of nonspecific and antigen specific immunities.

Animals↗
PubMed1999

Efficacy of a biological response modifier in preventing Staphylococcus aureus intramammary infections after calving.

A change in the epidemiology of mastitis in recent years has emphasized the role of the udder immune system in the pathogenesis of Staphylococcus aureus. Therefore, if the bovine or udder immune capability could be enhanced, susceptibility to Staph. aureus could be reduced and antibiotic efficacy could be increased. Immune system defense mechanisms could be enhanced by vaccination and by biological response modifiers. Within this latter group, a biological response modifier obtained from Parapox ovis that was attenuated over 200 tissue culture passages was recently developed and commercialized in some European countries. This study reports the results of a field trial on the efficacy of this biological response modifier in reducing Staph. aureus intramammary infection (IMI) after calving in primiparous and pluriparous cows. The trial included 106 cows sampled six times (55 cows from herd A and 51 from herd B) for a total of 2544 quarter milk samples. The analysis of IMI prevalence showed that 25.09% of samples were bacteriologically positive in the placebo group, and 23.17% of the positive samples were observed in the biological response modifier group. Staphylococcus aureus IMI had a frequency of 11.44% in the placebo group and 6.00% in the biological response modifier group. The dynamic of the hazards showed significantly lower rates in the biological response modifier group than in the placebo group (risk ratio = 0.47). Treatment with the parapox-containing biological response modifier showed significant reduction of Staph. aureus IMI around calving, and this reduction was attributed to an increase in immune defenses.

Adjuvants, Immunologic↗
PubMed2001

Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.

Co-administration of synthetic chemically modified oligonucleotides with irinotecan, a selective topoisomerase I inhibitor, provided a significant enhancement in the antitumor activity of irinotecan. The enhancement of antitumor activity of irinotecan with co-administration of chemically modified oligonucleotides was observed in several tumor models--pancreatic cancer (Panc-1), colon cancer (HCT-116) and melanoma (A375). Inhibition of tumor growth in all three models required the co-administration of irinotecan and chemically modified oligonucleotides, but was independent of the nucleotide sequence of the oligonucleotides. The potentiation of antitumor activity was dependent on the dose of irinotecan and chemically modified oligonucleotides administered. The enhancement of antitumor activity of irinotecan was also observed by co-administration of a phosphorothioate oligonucleotide, however, to a lesser extent than did chemically modified oligonucleotides, suggesting that metabolic stability of the oligonucleotide contributes to the enhancement of antitumor activity seen with irinotecan. The co-administration of dextran sulfate sodium with irinotecan showed insignificant potentiation of antitumor activity of irinotecan, suggesting that the enhancement of antitumor activity of irinotecan observed was not a result of polyanionic characteristic of oligonucleotides. Co-administration of irinotecan and chemically modified oligonucleotides did not result in increased toxicity in the tumor models studied. Potentiation of antitumor activity of irinotecan observed with co-administration of oligonucleotides suggests that the oligonucleotides affect the pharmacokinetics and/or metabolism of irinotecan. The use of chemically modified oligonucleotides together with irinotecan may increase the therapeutic index of irinotecan in cancer patients and continued development of such agents should be considered.

Animals↗
PubMed2000

[Evaluation of fetal well-being using a modified Doppler flowmetric profile].

Decreasing perinatal morbimortality rates still represents an essential objective of antenatal care, so better diagnostic test for detecting fetal well-being are needed. The aim of this study was to compare a modified Doppler Ultrasonography Profile (DUP) with the Manning Fetal Biophysical Profile (FBP). One hundred and thirty eight high risk pregnant women between 38 and 42 gestational age, were prospectively studied with the proposed technique. The modified DUP is a quick-easy method that included five variables: umbilical Doppler velocimetry, amniotic fluid volume, fetal movements, placental grading and fetal growth pattern. The modified DUP diagnostic accuracy was compared with FBP diagnostic accuracy and a logistical regression analysis was performed to find predictors of fetal well-being. The sensitivity, specificity, and positive and negative predictive values of DUP in predicting perinatal outcome were 28%, 97%, 40% and 96.2%, respectively. On the other hand sensitivity, specificity, and positive and negative predictive values of the FBP were: 20%, 91%, 11% and 95.6%, respectively. The 95% confidence intervals for sensitivity and specificity wore 20.7-25.2 and 94.5-99.4, for the modified DUP whereas were obtained for FBP 12.2-27.7 and 85.6-96.3. The concordance between evaluated tests was 89%, with a Kappa value of 0.80. The multivariate logistical analysis showed two predictor variables as significant in the modified DUP model (umbilical Doppler velocimetry, P < 0.05, and fetal growth pattern, P < 0.05) but in the FBP no parameter reached statistical significance. Although the modified DUP had better diagnostic values an overlapping was clearly found in 95% confidence intervals, therefore it was concluded that the modified DUP proposed had similar diagnostic accuracy as FBP and could be alternatively used for assessing fetal well-being in high-risk pregnancies.

Adolescent↗
PubMed2001

[Adsorption of TNF alpha onto the amino acid-modified NK-110 resin].

It is a effective way to remove Tumor Necrosis Factor(TNF alpha) from plasma by adsorbent. In the present study, NK-110 was modified by 8 amino acids to prepare the adsorbents to be used in the static adsorption experiments of TNF alpha. We have studied the adsorption capacity, kinetic profiles and adsorption isoterm of Cys modified NK-110, and some comparison were made between Cys modified NK-110 and unmodified one. The experimental results show that the Cys modified NK-110 exhibited superior adsorption capacity which is 7683.80 u/mL, and the adsorption percentage is 85.38% at 120 min in stable adsorption. Compared with unmodified NK-110, the Cys-modified one with high adsorption velocity. Furthermore, adsorption isotherms were also studied on Cys-modified and bare NK-110, bot showed to be of "L" shape at 37 degrees C. The adsorption amount increased as the concentration of TNF alpha increased, however, the adsorption percentage is stable adsorbed by Cys-modified NK-110, whereas it is decreased by bare one. The results demonstrating that Cys can significantly raised the adsorption capacity.

Adsorption↗
PubMed2002

Modifier genes for hypertrophic cardiomyopathy.

During the past decade, more than 100 mutations in 11 causal gene coding for sarcomeric proteins, the gamma subunit of AMP-activated protein kinase and triplet-repeat syndromes and in mitochondrial DNA, have been identified in patients with hypertrophic cardiomyopathy (HCM). Genotype-phenotype correlation studies show significant variability in the phenotype expression of HCM among affected individuals with identical causal mutations. Overall, causal mutations account for a fraction of the variability of phenotypes and genetic background, referred to as the modifier genes, play a significant role. The final phenotype is the result of interactions between the causal genes, genetic background (modifier genes), and probably the environmental factors. The individual modifier genes for HCM remain largely unknown, and a large-scale genome-wide approach and candidate gene analysis are needed. Current studies are limited to simple polymorphism association studies, which explore the association of functional single nucleotide polymorphisms in genes implicated in cardiac growth with the severity of the clinical phenotypes, primarily cardiac hypertrophy. Several potential modifier genes including genes encoding the components of the renin-angiotensin-aldosterone system have emerged. The most commonly implicated is an insertion/deletion polymorphism in the angiotensin-1 converting enzyme 1 gene, which is associated with the risk of sudden cardiac death and the severity of hypertrophy. Therapeutic interventions aimed at targeting the modifier genes have shown salutary effects in animal models of HCM. It has now recognized that modifier genes affect the expression of cardiac phenotype. Identification of the modifier genes will complement the results of studies of causative genes and could enhance genetic based diagnosis, risk stratification, and implementation of preventive and therapeutic measures in patients with HCM.

Animals↗
PubMed2002

Monophasic action potential mapping in swine and humans using modified-tip ablation catheter and electroanatomic mapping system.

OBJECTIVE: To evaluate the feasibility of monophasic action potential (MAP) mapping using a modified-tip NaviStar catheter in swine and humans. METHODS: MAP mapping was performed using the modified-tip catheter at 71 +/- 21 atrial and 60 +/- 16 ventricular sites in 10 healthy pigs and at 56 ventricular sites in one patient, and using an ordinary Navi-Star catheter at 30 atrial sites in one patient and 50 +/- 14 ventricular sites in four patients. In an additional 20 patients, MAPs were also recorded at 9 +/- 2 atrial sites using the modified-tip catheter or at 12 +/- 9 atrial sites using the ordinary catheter. RESULTS: In pigs, the plateau amplitudes of the MAPs recorded using the modified-tip catheter were 4.1 +/- 3.2 mV for the atrial and 9.5 +/- 4.3 mV for the ventricular MAPs. In patients, both the ventricular and atrial MAPs recorded using the modified-tip catheter were significantly higher than using the ordinary catheters, 15.7 +/- 8 and 3.0 +/- 0.9 mV vs 9.5 +/- 3.9 and 2.0 +/- 0.6 mV for the ventricular and atrial MAPs, respectively (p < 0.0001). The baseline disturbances were <10% of the MAP amplitude in 95% of the pig and 96% of the patient MAPs. CONCLUSION: A modified-tip Navi-Star catheter could be used in swine and in humans for prompt recording of MAPs with acceptable amplitudes and baselines. MAP mapping using the modified-tip catheter is safe and feasible for clinical use.

Action Potentials↗
PubMed1975

Treatment of carcinoma of the breast by modified radical mastectomy.

To evaluate the results of treatment of Stage I and Stage II-T1 and T2, NO and N1-carcinoma of the breast by modified radical mastectomy with preservation of the pectoralis major muscle, the survival rates of all such patients treated by the senior author from 1965 through 1968 were compared with the survival rates of a simultaneous group of patients with similar stage disease treated by conventional radical mastectomy by the same surgeon. There were a total of 134 patients, of whom 51 had modified radical mastectomy and 83 conventional radical mastectomy. The five year survival rate for those treated by standard radical mastectomy was 81 per cent, and for those treated by modified radical mastectomy, it was 84 per cent. In patients with histologically negative axillary lymph nodes, the rates were 86 per cent following both radical mastectomy and modified radical mastectomy. Four per cent of the surviving patients after modified radical mastectomy and 7 per cent of the five year survivors after radical mastectomy had evidence of metastases at five years. Locally recurrent disease was noted in 5 per cent of those who had modified radical mastectomy and 7 per cent of those who underwent standard radical mastectomy. This analysis demonstrates that there is no significant difference in the survival and recurrence rates after conventional radical mastectomy and ,odified radical mastectomy of the Patey type. There is a high incidence of recurrence-free survival after both of these operations. Since modified radical mastectomy is less traumatic, involving less damage to muscular tissues, and is followed by significantly decreased deformity, it is advised as the treatment of choice for patients with carcinoma of the breast having no or minimal evidence of axillary node involvement. More extensive tumors adherent to the pectoral fascia or associated with multiple or large palpable axillary nodes should still be treated by conventional radical mastectomy.

Adult↗
PubMed1975

Mixed lymphocyte reactivity and cell-mediated lympholysis to trinitrophenyl-modified autologous lymphocytes in C57BL/10 congenic and B10-A recombinant mouse strains.

Cell-mediated lympholysis (CML) to trinitrophenyl (TNP)-modified autologous splenic lymphocytes has been recently reported in the mouse (1). Both the sensitization and effector phases of this phenomenon were shown to be T-cell mediated. Effector cell specificity studies indicated that modification of the target cells is a necessary but insufficient requirement for cytolysis, and suggested that altered cell surface components controlled by genes mapping in the mouse major histocompatibility H-2 complex (MHC) are important in the specificity of the cytotoxic reaction (1). In allogeneic models the generation of cytotoxic effector cells has been shown to be preceded or accompanied by immunogen- induced proliferation of responding lymphocytes, i.e. a mixed lymphocyte reaction (MLR) (2-5), although the generation of effectors may not necessarily always be the consequence of extensive cell proliferation (5). If the induction of cytotoxic effector lymphocytes by modified syngeneic spleen cells is characteristic of sensitization with cellular alloantigens, one would expect to find that sensitization with TNP-modified autologous cells would also induce thymidine incorporation by the responding cells in the culture. The present report demonstrates that both stimulation of thymidine incorporation and generation of cytotoxic effector cells are part of the in vitro response to TNP-modified autologous lymphocytes. However, the MLR to TNP- modified autologous cells consistently appeared to be less pronounced when compared with an allogeneic MLR, whereas the cytotoxic activity of the effector cells generated by sensitization against TNP-modified autologous cells was frequently as high as that detected against H-2 alloantigens. These two components of reactivity to "modified self" are verified in several C57BL/10 congenic and B10.A recombinant mouse strains.

Animals↗
PubMed2000

[Effects of modified SD therapy on Bell's palsy].

OBJECTIVE: To investigate the effects of a modified SD therapy (intravenous high dose hydrocortisone and low molecular dextran) on Bell's palsy(BP), and to avoid the severe side-effects such as hepatic and renal disorders during the treatment. METHOD: Seventy-one BP patients were treated with modified SD method (modified group), thirty-two BP patients took prednisone (control group), and the curative rates of two therapies were compared, in the meanwhile recorded the side effects in detail. RESULT: Curative rate in modified group was 95.8% (House-Brakmsnn I-II) and in control group was 81.2% (P < 0.05). In modified group, the curative rate (I grade) in the patients were treated within 24 hours following onset was 75.0%, and the curative rate in other three subgroups were treated within 24-48 hours, 2-3 day and 3-5 day following onset was 43.8%, 26.7%, 18.8% respectively. Modified group had not shown hepatic and renal disorders or gastric ulcer. CONCLUSION: Modified SD method may increase recoverable rate and can avoid significant side effects for BP, and emphasizes the importance of the administration of SD therapy in the early stage of the disease.

Adult↗
PubMed2003

Asthma: resource use and costs for inhaled corticosteroid vs leukotriene modifier treatment--a meta-analysis.

OBJECTIVE: To compare the effects of inhaled corticosteroid treatment with leukotriene modifier treatment on medical resource use and costs for asthma patients. STUDY DESIGN: Meta-analysis combining results from published and unpublished studies. DATA SOURCES: Studies were identified from the MEDLINE and EMBASE databases and the GlaxoSmithKline internal database study registers. Two independent reviewers evaluated the identified studies; studies meeting specified inclusion criteria were abstracted and summarized by meta-analysis with a random effects model. OUTCOMES MEASURED: Hospitalization rate, emergency department visit rate, emergency department costs, drug costs, total asthma-related costs, and total medical care costs. RESULTS: Patients taking inhaled corticosteroids had: a significantly lower annual rate of hospitalization than those taking leukotriene modifiers (2.2% vs 4.3%, respectively; P<.05); a greater decline in hospitalization rate (before vs after therapy initiation) than those taking leukotriene modifiers (decline of 2.4% vs 0.55%; P<.01); a lower annual rate of emergency department visits than those taking leukotriene modifiers (6.2% vs 7.7%; P<.005); lower total asthma-related medical costs than those taking leukotriene modifiers (P<.05) and a 17% reduction in overall total medical care costs (P not significant). CONCLUSIONS: Patients with asthma treated with inhaled corticosteroids have significantly fewer asthma-related hospitalizations and emergency department visits and lower total asthma-related health care costs than patients treated with leukotriene modifiers. These meta-analysis findings are consistent with results from randomized controlled trials showing improvements in lung function for patients taking inhaled corticosteroids as opposed to leukotriene modifiers.

Administration, Inhalation↗
PubMed2003

10 years of mouse cancer modifier loci: human relevance.

About 10 years have elapsed since the first whole-genome scanning studies in the mouse to identify loci that affect susceptibility or resistance to tumorigenesis. In that time, >100 cancer modifiers have been mapped, and four strong candidate genes have been identified. Cancer modifier loci affect almost all types of mouse tumorigenesis, with some loci acting on the entire tumorigenic process, whereas others act on specific stages, e.g., tumor initiation or tumor growth/progression. Present evidence indicates that the effects of cancer modifier loci are tissue-specific and restricted to tumor cells. However, a subset of such loci may be involved in different types of tumors, and several chromosomal regions show significant clustering of cancer modifier loci. Human homologues of mouse cancer modifier loci most likely exist and play a role in the risk of sporadic cancer, although present experimental evidence for this possibility is sparse. Mouse cancer modifier loci might serve as the basis for understanding the genetic and biochemical mechanisms of polygenic inheritance of cancer predisposition/resistance. Identification of homologous cancer modifier loci in humans might, in turn, provide a step toward the development of diagnostic, preventive, and therapeutic strategies that target these loci.

Animals↗
PubMed2003

Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.

PURPOSE: The purpose of this study was to evaluate the immunological responses and therapeutic effectiveness of immunization with fowlpox vaccines encoding the gp100 melanoma antigen in patients with metastatic melanoma. EXPERIMENTAL DESIGN: In three consecutive clinical trials, patients were immunized with recombinant fowlpox viruses encoding three different forms of the melanoma/melanocyte-associated antigen gp100: (a) the native, full-length gp100 molecule; (b) the gp100 molecule with two amino acids modified to increase binding to HLA-A*0201 molecules; and (c) a "minigene" construct encoding a single, modified epitope gp100:209-217(210M) targeted to the endoplasmic reticulum. The immunogenicity of these constructs was studied using peripheral blood mononuclear cells to measure epitope-specific release of IFN-gamma. RESULTS: Reactivity against gp100 was not seen in any patient before receiving fowlpox immunization. Whereas just one of seven patients developed reactivity after receiving fowlpox encoding native gp100, 10 of 14 patients who received fowlpox encoding the anchor modified full-length gp100 exhibited reactivity against the native gp100 molecule, and 12 of 16 patients were successfully immunized after inoculation with the modified minigene construct (p2 = 0.02). There was no difference in the latter group between those randomized to vaccination by i.v. or i.m. routes. There was one partial cancer regression in the group of 46 patients receiving virus in the absence of interleukin (IL)-2. Once patients showed evidence of progressive disease, they were eligible for "cross-over" treatment to IL-2 alone or with the fowlpox virus. None of the 13 patients receiving the full-length or modified full-length forms of gp100 responded when receiving IL-2, whereas 6 of 12 patients who received the fowlpox containing the minigene construct and then received IL-2 showed objective cancer regressions, including three patients with complete regression. CONCLUSIONS: These data underscore the importance of modifying anchor residues of nonmutated self-antigen peptides to generate cellular immune responses after immunization and support the further investigation of recombinant fowlpox viruses encoding modified epitopes administered in combination with IL-2.

Adult↗
PubMed2003

[Comparison of tolerance to sequential continuous positive airway pressure therapy between patients after classical and after modified uvulopalatopharyngoplasty].

OBJECTIVE: To investigate the effect of uvulopalatopharyngoplasty (UPPP) on postoperation continuous positive airway pressure (CPAP) treatment in patients with obstructive sleep apnea hypopnea syndrome (OSAHS). METHODS: 66 OSAHS patients underwent UPPP were recruited and all were followed up for more than 12 months. Among them 24 patients were treated with classical UPPP, 42 had modified UPPP treatment. The efficacy of surgery was compared between the two groups. The post-operation tolerance to CPAP pressure was tested during sleep CPAP titration in 24 classical UPPP patients and in 15 modified UPPP patients. RESULTS: The validity ratio is 58.3% and 61.9% 12 months after operation. There was no significant difference between classical UPPP and modified UPPP in regard to surgery efficacy, and most of them need further CPAP therapy. During CPAP treatment, compared with untreated OSAHS patients, the highest CPAP pressure classical UPPP group could tolerant decreased significantly, however, classical UPPP group did not. 16.7% of classical UPPP patients had severe mouth air leak before optimal CPAP pressure was titrated, but none of the 15 post modified UPPP failed to sequential CPAP therapy. CONCLUSION: The efficacy was similar between modified UPPP and classical UPPP treatment, post modified UPPP patients had better tolerance to sequential CPAP treatment. It may be better to treat OSAHS patients with modified UPPP instead of classical UPPP.

Adult↗